Pleconaril - Apodemus

Drug Profile

Pleconaril - Apodemus

Alternative Names: APO-P001

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apodemus
  • Class Antivirals; Oxadiazoles; Small molecules
  • Mechanism of Action RNA inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 13 Sep 2017 Oslo University Hospital plans a phase II trial for Type-1 diabetes in Sweden (EudraCT2015-003350-41)
  • 04 Sep 2016 Apodemus terminates a phase II clinical trial in Amyotrophic lateral sclerosis (Combination therapy) in Sweden (PO)
  • 23 Jun 2016 Apodemus completes a phase-II clinical trial in Alzheimer's disease (Combination therapy) in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top